Perlegen will use these samples to identify genetic variations that may contribute to a patient’s risk of experiencing adverse events. Results of these analyses may help to direct patients to the drug that is most appropriate for their use, and may provide researchers with important new targets or pathways for drug discovery and development. The company has licensed its own phase III ready thiazolidinediones (TZDs) from Mitsubishi Pharma. TZD drugs are linked to fluid retention and weight gain which affects the heart.
“Our early results have demonstrated a significant genetic component to the adverse effect profile of these TZDs,” commented David R. Cox, Perlegen’s chief scientific officer, “Through our analysis of this valuable sample set, using both genotyping and sequencing technologies, we hope to provide patients and physicians with critical decision making information, while revealing biological insights that will enable the discovery of safer medicines.”